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Correcting genetic mutations in human cells
Many genetic diseases are caused by the 
mutation of a single DNA base in a 
particular gene.
Genome editing uses a customised 
enzyme that cuts DNA at a single site in 
the genome, close to the site of the 
mutation. 
The natural repair processes inside the cell 
then repair the damaged DNA, and if an 
additional DNA 'template' is added to the 
cell, the repair processes will often replace 
a short piece of the cell's original DNA with 
the new sequence from the template. 
Genome editing to correct Rett syndrome mutations
TALEN proteins can be 
designed to bind and cut 
virtually any sequence in 
the genome
We have optimised versions of TALENs 
(v2, v3) with improved cutting efficiency 
and improved specificity
Picture from Rett Syndrome Research Trust
• Rett syndrome is a genetic disorder caused by 
mutations in the gene MECP2. 
• It affects 1 in 10,000 girls, and becomes apparent 
at age 1 – 2 . Average female life expectancy ~40’s
• Features include loss of movement control, loss of 
speech, compulsive hand movements, and 
problems with breathing, sleeping and digestion.  
Our collaborators, Stuart Cobb and 
Mark Bailey, have shown that Rett
syndrome can be reversed in adult mice 
by expressing the correct form of 
MECP2.
A virus was used to deliver MECP2 to 
Rett mutant mice, and significant 
improvements in survival were 
observed, along with a reduction in the 
severity of symptoms.
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We have also created 
TALE repressor proteins 
that can turn off the 
expression of a target gene
Regular blood transfusions are essential for 
those with genetic disorders affecting red blood 
cells (thalassaemias). 
However, donated blood is not available in all 
countries, and carries the risk of transmitting 
infections between people such as hepatitis or 
HIV.
Jo Mountford’s group at the University of 
Glasgow have developed a method for  
generating high volumes of red blood cells from 
pluripotent stem cells grown in the lab. 
Red blood cells made in the lab produce foetal 
haemoglobin, which binds oxygen more tightly 
than adult haemoglobin. This blood is not ideal 
for transfusion, particularly for weak and 
vulnerable patients. 
Genetic engineering of red blood cells for transfusion
embryo foetus adult
b-globin genes
The red blood cells that will be given to 
patients have no DNA and are irradiated, 
removing any risk of infection or cancer.
We are developing genome editing technology to remove the foetal b-globin genes and 
force the cells to produce adult b-globin. This will mean the synthetic red blood cells are 
more efficient at taking oxygen to where it’s needed in the body.
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Survival and symptom severity of mice following 
injection of virus expressing MECP2
Gadalla et al, 2013. Mol. Therapy 21:18-30
Repression of gene 
expression by specific 
TALE Repressor  proteins
Level of protein made 
by target gene
Genome editing resulting from TALEN activity is 
shown by increased amounts of the red 578 band.
Version 2 and 3 TALENs have greatly increased 
performance compared to standard TALENs
We are developing genome editing 
strategies to correct mutations in the 
endogenous MECP2 gene. This would 
remove the risk of expressing too much 
MECP2 protein from the viral vector, 
which could cause mental and physical 
disabilities.
Strategy to correct mutated MECP2 gene
